News Search Results
May 15, 2025, 07:30 ET Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may
More news about: Elevation Oncology
May 15, 2025, 05:45 ET Investors in Sana Biotechnology, Inc. Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA
May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
May 15, 2025, 01:22 ET 2025 ASGCT | Immunofoco's In Vivo CAR-T Technology Platform Debuts with Groundbreaking Innovations
https://www.prnewswire.com/news-releases/2025-asgct--immunofocos-in-vivo-car-t-technology-platform-debuts-with-groundbreaking-innovations-302456246.html SOURCE Immunofoco Biotechnology
More news about: Immunofoco Biotechnology
May 15, 2025, 01:04 ET Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions
collaborators, and strategic investors to expand diagnostic access and co-develop market-specific solutions. About Anbio Biotechnology Anbio Biotechnology is a globally oriented IVD company focused on empowering healthcare professionals through innovative diagnostic solutions. Its portfolio
More news about: Anbio Biotechnology
May 14, 2025, 17:31 ET Akeso's Penpulimab Approval Intensifies the Competition Among the Other Pharmaceutical Companies Active in the Nasopharyngeal Carcinoma Market | DelveInsight
companies, including Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences,
More news about: DelveInsight Business Research, LLP
May 14, 2025, 17:27 ET Aspen Neuroscience to Present at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Louisiana. The annual meeting, the largest gathering of cell and gene therapy professionals, hosts a global audience of attendees from academia, the biotechnology and pharmaceutical industries, government, and non-profit patient foundations. "We are excited to be part of this meeting, which covers the
More news about: Aspen Neuroscience, Inc.
May 14, 2025, 17:27 ET GordonMD Global Investments® Welcomes Cellarity's Appointment of Ted Myles as Chief Executive Officer, Strengthening Leadership Amid Scientific and Program Progress
working with Ted and the team as they develop more treatments to meet wide-ranging patient needs." "Cellarity is a powerhouse of AI-powered biotechnology," said Ted Myles, CEO of Cellarity. "Its end-to-end platform and bold scientific vision are unmatched. I'm excited
More news about: GordonMD Global Investments®
May 14, 2025, 16:05 ET Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
May 14, 2025, 16:05 ET MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March
More news about: MetaVia Inc.
May 14, 2025, 16:01 ET Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
$ 29,603 About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
May 14, 2025, 11:00 ET Stephen Wright, MD, Joins BRC Therapeutics as Development Advisor
field and continues to have major impact on innovation in drug development." Dr. Wright has over 30 years of experience in the biotechnology and pharmaceuticals industry, having played a key role in the development of Epidiolex®, the first FDA-approved prescription cannabidiol
More news about: BRC Therapeutics
May 14, 2025, 10:46 ET Minimalist Routine, Maximalist Results: GRAES Launches with 8-in-1 Night Cream to Combat "Beauty Burnout"
friends and family, I could see their eyes light up in recognition. That's why I started GRAES," said Martin. Drawing on her background in biotechnology and immunology, Martin spent years researching ingredients and identifying over 350 known irritants and sensitizers—none of which are included in
More news about: GRAES
May 14, 2025, 10:09 ET 25th Global Family Office Investment Summit in Dubai Co-Hosted by Anthony Ritossa and Lives Amplified Global Institution of World Leaders Celebrates a Decade of Impact and Innovation
transformation in just five years. Exponential advancements in artificial intelligence, immersive computing, decentralized finance, and biotechnology are redefining the way we live, work, and invest. Unlimited Awesome is building the next generation of innovators and change-makers." "I
More news about: Ritossa Family Office
May 14, 2025, 10:01 ET CRISPR Market worth US$5.47 billion by 2030 with 11.2% CAGR | MarketsandMarkets™
academia, biotechnology, and the pharmaceutical industry. By Based on end users, the CRISPR services market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. Among these, pharmaceutical & biotechnology companies
More news about: MarketsandMarkets
May 14, 2025, 09:30 ET Rgenta Therapeutics Announces Presentation of Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, at the European Hematology Association (EHA) 2025 Congress
Mass. , May 14, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders,
More news about: Rgenta Therapeutics
May 14, 2025, 09:00 ET Nortian Secures $41M to Launch U.S. Manufacturing Operations & Lead the High-Protein Ecosystem Revolution
[email protected] About Nortian Founded in 2024, Nortian is a U.S.-based biotechnology company pioneering the production of ultra-pure collagen from hide through a proprietary, vertically integrated process. Designed for use across
More news about: Nortian
May 14, 2025, 08:55 ET AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
May 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today announced a collaboration and license option agreement to develop small interfering RNA
More news about: AbbVie
May 14, 2025, 07:30 ET Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
May 14, 2025, 07:13 ET FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
correlate with neurocognitive manifestations of the disorder. About REGENXBIO Inc.REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development
More news about: NS Pharma, Inc.
May 14, 2025, 07:00 ET CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Alan Glicklich, M.D., to the Company's Board of Directors. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics. Previously, he was Chief Medical Officer of Chinook Therapeutics.Other
More news about: CalciMedica, Inc.
May 14, 2025, 05:52 ET Noster research: Gut bacteria-derived molecule found to shrink fat cells and improve metabolism
(stearoyl-CoA desaturase 1), CPT1A (carnitine acyltransferase 1A), GPR (G protein-coupled receptor) About Noster Inc. Noster Inc. is a biotechnology company based in Kyoto, Japan. The company focuses on postbiotics—compounds produced by gut bacteria—to develop
More news about: Noster Inc
May 14, 2025, 03:30 ET Kaerus Bioscience's lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS)
Phase 2 proof-of-concept study in FXS patients. About Kaerus Backed by Medicxi, Kaerus Bioscience Ltd is a clinical-stage biotechnology company committed to turning scientific advances into treatment realities for patients with rare genetic syndromes of neurodevelopment. Kaerus has
More news about: Kaerus Bioscience
May 14, 2025, 02:04 ET Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities
combines scientific leadership, operational excellence, and a global network of research sites to deliver tailored solutions for pharmaceutical, biotechnology, and partners. For more information, visit
More news about: Julius Clinical Research
May 13, 2025, 17:00 ET Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
reach out to your respective H.C. Wainwright representative. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
May 13, 2025, 17:00 ET Rgenta Therapeutics Presents Data from Proprietary RSwitch Technology Demonstrating Versatile, Tunable Transgene Expression in AAV-Delivered Gene Therapies with Orally Administered Small Molecules (RDrugs)
Mass., May 13, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders,
More news about: Rgenta Therapeutics